The tools exist to end cervical cancer in this lifetime, yet providers and patients are still in the early stages of learning and understanding the new screening guidelines and what screening options are available and for whom. This gap has real consequences, with about a quarter of women being behind on cervical cancer screenings. Confusion about what tests to take, and when, persists, with many clinicians and patients conflating Pap smears and HPV testing. In fact, cotesting offers limited clinical value despite its common use in the United States. This misunderstanding isn’t just a technical detail, it shapes care decisions, testing frequency, and outcomes.
The Pap smear has long been synonymous with cervical cancer screening – and for good reason. Since its widespread adoption in the 1940s, the Pap has saved countless lives by identifying precancerous changes early on. For decades, it was the only tool we had, and patients received it annually, given its lower sensitivity in detecting abnormal cells. But the science and guidelines around cervical cancer screenings have evolved dramatically, and many clinicians and patients are struggling to keep up. The biggest area of confusion is the difference between a Pap smear and HPV (human papillomavirus) testing – and which one patients should actually be getting.
A Pap smear examines a sample of superficial cervical cells under a microscope to detect abnormalities that could point to precancer or cancer. It still requires a speculum exam to collect that sample. HPV testing is more targeted, looking for the DNA or RNA of 14 high-risk strains of HPV, the virus responsible for nearly all cervical cancers. While the Pap identifies the cell changes, the HPV test determines the root cause before those changes even happen. Both tests have saved lives. But they are not interchangeable, and treating them as such puts the patient at risk.
The confusion is understandable. Culturally, “Pap smears” became shorthand for any cervical cancer screening visit, done annually and expected at every OB-GYN appointment. As science evolved, so did the guidelines. Once researchers identified persistent HPV infection as the primary driver of cervical cancer, screening expanded beyond the Pap smear alone, first using HPV testing to follow up on abnormal results, and now, in many cases, as the primary screening tool itself. If HPV was detected, closer monitoring with repeat testing or a colposcopy was indicated. Eventually, HPV testing was recommended in combination with Pap smears for all women 30 and older, called the co-test. And because a negative HPV test is such a strong negative predictor of cervical cancer and precancerous changes, the recommended screening interval increased from every 3 to every 5 years. Today, leading institutions like the American Cancer Society and American College of Obstetrics and Gynecologists recommend primary HPV testing as the preferred screening method, rendering the Pap smear unnecessary unless HPV strains are detected. Importantly, this approach also makes self-collection possible – a significant advancement in expanding access to screening.
Yet the old habits persist. One in five women is unaware of her HPV testing status. Providers and patients are so used to screening annually, but that’s an outdated practice that might cause increased patient anxiety, a fragmented care experience, and diminished trust in the healthcare system. The Pap smear’s cultural dominance is now one of the barriers to better cervical cancer outcomes.
Providers and their clinics can play a huge role in shifting this. The fix starts with language. Electronic health records may distinguish between HPV and Pap results behind the scenes, but that nuance rarely translates to how patients experience care. A clearer opportunity is at the front end: how appointments are named and described. Instead of defaulting to a “Pap smear” or “Pap test” visit, providers could adopt standardized language like “cervical screening” as they use in the U.K., and specify in advance which test(s) may be performed, HPV testing, a Pap smear, or both. This small shift would better reflect current guidelines and help set clearer expectations for patients. Standardized follow-up guidelines and patient education are essential. Clinicians should communicate clearly: a negative HPV test is a powerful predictor that cervical cancer or precancerous changes are extremely unlikely – and that a Pap smear is not needed at that time. Modern guidelines and research underscore that, whenever available, HPV testing should be the first line of defense against cervical cancer. The Pap smear should be reserved for when there is a clinical indication to have the cervical cells evaluated. Aligning practice with evidence doesn’t just simplify care; it prevents cancer before it starts.
The stakes extend beyond individual patient care. Misunderstanding screening methods can lead to overtesting, wasted resources, and an erosion of the trust patients place in their providers and the healthcare system at large. The Pap smear earned its place in medical history. Now the healthcare system owes patients the same commitment to the tools that will define the next century of cervical cancer prevention, with self-collection tests, which can be done at home, that are just as accurate as in-office clinical tests. Offering at-home self-collect HPV testing will help close the screening gaps and greatly reduce the number of cervical cancer cases, moving towards a goal of eliminating cervical cancer in the United States.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Photo: BlackSalmon, Getty Images
Dr. Liz Swenson is a board-certified OB/GYN who has been providing care to women for more than 20 years. She has learned that women are genuinely interested in their own health and want to understand the science behind their medical conditions. Originally from Iowa, she completed her medical training in Northern California where she still lives with her husband and two daughters. She has worked in a busy multispecialty practice in Palo Alto and has taught OBGYN residents as an Adjunct Clinical Faculty Member of Stanford University. Now, with a focus on helping all women have choices and access to the gynecological care they need, she is excited to be using her clinical experience to help improve the lives and longevity of all Teal patients.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.